Severe lorlatinib-induced dyslipidaemia successfully managed with a PCSK9 inhibitor in a patient with ALK-positive non-small cell lung cancer: A case report
Severe lorlatinib-induced dyslipidaemia successfully managed with a PCSK9 inhibitor in a patient with ALK-positive non-small cell lung cancer: A case report. // Journal of Clinical and Translational Endocrinology: Case Reports. – URL: https://www.sciencedirect.com/science/article/pii/S2214624526000158?dgcid=rss_sd_all
Severe lorlatinib-induced dyslipidaemia successfully managed with a PCSK9 inhibitor in a patient with ALK-positive non-small cell lung cancer: A case report. Journal of Clinical and Translational Endocrinology: Case Reports. https://www.sciencedirect.com/science/article/pii/S2214624526000158?dgcid=rss_sd_all
“Severe lorlatinib-induced dyslipidaemia successfully managed with a PCSK9 inhibitor in a patient with ALK-positive non-small cell lung cancer: A case report.” Journal of Clinical and Translational Endocrinology: Case Reports.
@article{article4271,
title = {Severe lorlatinib-induced dyslipidaemia successfully managed with a PCSK9 inhibitor in a patient with ALK-positive non-small cell lung cancer: A case report},
journal = {Journal of Clinical and Translational Endocrinology: Case Reports},
url = {https://www.sciencedirect.com/science/article/pii/S2214624526000158?dgcid=rss_sd_all}
}